Pediatrix Medical Group (NYSE:MD) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Pediatrix Medical Group (NYSE:MD) issued its earnings results on Tuesday. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07, FiscalAI reports. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The firm had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. During the same quarter last year, the company posted $0.33 earnings per share. The firm’s revenue was up 3.9% compared to the same quarter last year.

Here are the key takeaways from Pediatrix Medical Group’s conference call:

• Pediatrix reported a strong Q1 with adjusted EBITDA of $58 million driven by top-line growth and 4% pricing, and management reaffirmed the full-year adjusted EBITDA outlook of $280–$300 million.
• Pricing growth (~4%) was driven by RCM cash collections (about 25% of the quarter’s pricing lift), contract admin fees (10–20%), favorable payer mix and higher neonatology acuity, but management expects RCM-driven gains to moderate and is maintaining a flat pricing outlook for the year.
• Same-unit volumes showed modest declines (NICU days down ~1%), and although management says there is no clear multiquarter trend yet, sustained volume weakness would be a downside risk to revenue and EBITDA.
• Balance sheet and capital allocation activity remain constructive—Q1 used ~$130 million of operating cash (seasonal incentive payouts), repurchased $21 million of stock, ended the quarter with just over $200 million cash and net debt of just over $385 million (~1.3x net leverage at midpoint).
• Leadership and strategic moves emphasize quality and growth—Pediatrix hired two high-profile clinical quality leaders, launched a clinician partner equity program, and is targeting expanded telehealth and OB/MFM services to deepen hospital partnerships.

Pediatrix Medical Group Price Performance

Shares of NYSE MD traded down $1.82 during trading on Tuesday, hitting $20.59. The company had a trading volume of 829,738 shares, compared to its average volume of 776,081. The stock has a fifty day simple moving average of $20.96 and a two-hundred day simple moving average of $21.21. Pediatrix Medical Group has a fifty-two week low of $11.84 and a fifty-two week high of $24.99. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 10.62 and a beta of 0.70. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.66.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors and hedge funds have recently bought and sold shares of MD. Global Retirement Partners LLC boosted its position in Pediatrix Medical Group by 68,250.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock worth $29,000 after acquiring an additional 1,365 shares during the last quarter. Transamerica Financial Advisors LLC acquired a new position in Pediatrix Medical Group during the fourth quarter worth about $30,000. Los Angeles Capital Management LLC acquired a new position in Pediatrix Medical Group during the fourth quarter worth about $43,000. Kemnay Advisory Services Inc. acquired a new position in Pediatrix Medical Group during the fourth quarter worth about $71,000. Finally, Canada Pension Plan Investment Board acquired a new position in Pediatrix Medical Group in the 2nd quarter valued at about $83,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group News Summary

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Q1 results topped expectations — EPS of $0.44 and revenue of $476.2M beat consensus, showing steady profit improvement vs. a year ago. Zacks: Q1 Results
• Positive Sentiment: Company reaffirmed 2026 adjusted EBITDA guidance of $280M–$300M, indicating management expects continued margin/price benefits into the year. Seeking Alpha: Guidance Reaffirmed
• Positive Sentiment: Profitability metrics remain healthy (ROE ~19.6%, net margin ~8.6%), supporting cash generation and valuation metrics (P/E ~10.8). MarketBeat: Earnings Snapshot
• Neutral Sentiment: Management commentary and the full earnings call transcript are available for investor review — useful to parse cadence on volumes, reimbursement and M&A/labor outlook. Seeking Alpha: Call Transcript
• Neutral Sentiment: Multiple recaps and transcripts (Fool, MSN, AP) cover the quarter and management remarks — good sources if you want quotes and segment detail. Fool: Transcript MSN: Revenue Beat
• Negative Sentiment: Management noted “modest” volume declines that pricing gains are offsetting; investors may view persistent volume pressure as a risk to topline sustainability if pricing or mix reverses. Seeking Alpha: Volume Commentary
• Negative Sentiment: No upward revision to full-year targets despite the beat — some traders likely sold into strength, leaving the stock lower on the day. AP: Earnings Snapshot

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. UBS Group cut their price objective on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a report on Tuesday, February 24th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Pediatrix Medical Group in a report on Monday, April 20th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a report on Friday, February 20th. Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a report on Monday, April 13th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $21.33.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.